DK2211846T3 - Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser - Google Patents

Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser

Info

Publication number
DK2211846T3
DK2211846T3 DK08854467.1T DK08854467T DK2211846T3 DK 2211846 T3 DK2211846 T3 DK 2211846T3 DK 08854467 T DK08854467 T DK 08854467T DK 2211846 T3 DK2211846 T3 DK 2211846T3
Authority
DK
Denmark
Prior art keywords
cmt
approaches
treatment
related disorders
hitherto unknown
Prior art date
Application number
DK08854467.1T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Application granted granted Critical
Publication of DK2211846T3 publication Critical patent/DK2211846T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK08854467.1T 2007-11-30 2008-11-28 Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser DK2211846T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
DK2211846T3 true DK2211846T3 (da) 2013-04-29

Family

ID=39264515

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12196650.1T DK2609916T3 (da) 2007-11-30 2008-11-28 Nye terapeutiske tilgange til behandling af CMT og relaterede lidelser
DK08854467.1T DK2211846T3 (da) 2007-11-30 2008-11-28 Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12196650.1T DK2609916T3 (da) 2007-11-30 2008-11-28 Nye terapeutiske tilgange til behandling af CMT og relaterede lidelser

Country Status (24)

Country Link
US (6) US8992891B2 (da)
EP (4) EP2065038A1 (da)
JP (4) JP5953000B2 (da)
KR (1) KR101546031B1 (da)
CN (2) CN101883561B (da)
AU (1) AU2008328745B2 (da)
BR (1) BRPI0819678A2 (da)
CA (3) CA3031484C (da)
CY (2) CY1113980T1 (da)
DK (2) DK2609916T3 (da)
EA (3) EA035711B1 (da)
ES (3) ES2831855T3 (da)
HR (2) HRP20130345T1 (da)
HU (1) HUE040596T2 (da)
IL (1) IL205741A0 (da)
LT (1) LT2609916T (da)
MX (1) MX2010005709A (da)
NZ (1) NZ585440A (da)
PL (2) PL2609916T3 (da)
PT (2) PT2609916T (da)
SI (2) SI2211846T1 (da)
TR (1) TR201819564T4 (da)
WO (1) WO2009068668A1 (da)
ZA (1) ZA201003610B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
WO2011061304A1 (en) * 2009-11-20 2011-05-26 Pharnext New diagnostic tools for charcot-marie-tooth disease
CN102811716B (zh) * 2010-01-15 2017-08-25 国立健康与医学研究所 用于治疗孤独症的化合物
ES2647368T3 (es) * 2010-10-08 2017-12-21 Vib Vzw Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
US10016142B2 (en) 2012-10-19 2018-07-10 Sidewaystrategies Llc Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
SMT201800534T1 (it) 2013-06-05 2019-01-11 Pharnext Soluzioni orali stabili per principi attivi farmaceutici combinati
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
WO2015124763A1 (en) * 2014-02-24 2015-08-27 Pharnext New compositions for treating mechanical neuronal injuries
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2018014007A1 (en) 2016-07-14 2018-01-18 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
WO2018076060A1 (en) * 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
AU2020254610A1 (en) 2019-04-01 2021-11-18 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
CN115996725A (zh) * 2020-05-01 2023-04-21 应用治疗公司 用于治疗山梨糖醇脱氢酶缺乏症的醛糖还原酶抑制剂
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
CN118679159A (zh) * 2022-01-29 2024-09-20 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途
EP4497437A4 (en) * 2022-03-22 2025-03-12 Kyoto University MEDICINES FOR THE TREATMENT OR PREVENTION OF CHARCOT-MARIE-TOOTH DISEASE

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
CA2305179A1 (en) 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Oral administration preparation
WO2000017358A2 (en) * 1998-09-22 2000-03-30 Incyte Genomics, Inc. Human chaperone proteins
JP2002526417A (ja) * 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ，インコーポレイテッド 非甲状腺性疾患の治療方法
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
ATE510534T1 (de) * 2002-03-14 2011-06-15 Euro Celtique Sa Naltrexonhydrochlorid-zusammensetzungen
AU2003220551A1 (en) * 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
CA2495917A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
KR101170844B1 (ko) * 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
WO2005032555A2 (en) * 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050191343A1 (en) 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
WO2007134136A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
ATE511392T1 (de) 2007-01-11 2011-06-15 Xenoport Inc Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
SMT201800534T1 (it) 2013-06-05 2019-01-11 Pharnext Soluzioni orali stabili per principi attivi farmaceutici combinati
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
IL205741A0 (en) 2010-11-30
CN104257657B (zh) 2017-07-04
LT2609916T (lt) 2019-02-11
ES2831855T3 (es) 2021-06-09
ES2408785T3 (es) 2013-06-21
JP2011504915A (ja) 2011-02-17
ZA201003610B (en) 2011-06-29
US20180360785A1 (en) 2018-12-20
EP2065038A1 (en) 2009-06-03
BRPI0819678A2 (pt) 2017-05-09
AU2008328745B2 (en) 2014-01-30
NZ585440A (en) 2011-12-22
AU2008328745A1 (en) 2009-06-04
EP2609916B1 (en) 2018-11-07
EA201791669A3 (ru) 2018-03-30
CA3031490C (en) 2021-05-04
KR20100088160A (ko) 2010-08-06
EA201301078A1 (ru) 2014-06-30
PT2211846E (pt) 2013-05-10
CN101883561A (zh) 2010-11-10
PL2609916T3 (pl) 2019-03-29
US10463640B2 (en) 2019-11-05
JP6608309B2 (ja) 2019-11-20
US20180250289A1 (en) 2018-09-06
JP2016145227A (ja) 2016-08-12
US20150157626A1 (en) 2015-06-11
JP2019142917A (ja) 2019-08-29
KR101546031B1 (ko) 2015-08-25
US20100310641A1 (en) 2010-12-09
PT2609916T (pt) 2019-01-10
HRP20182147T1 (hr) 2019-03-08
EA201791669A2 (ru) 2017-12-29
SI2211846T1 (sl) 2013-07-31
JP2018109043A (ja) 2018-07-12
EP2211846A1 (en) 2010-08-04
MX2010005709A (es) 2010-11-05
EP2211846B1 (en) 2013-02-27
DK2609916T3 (da) 2019-01-21
CA2705408A1 (en) 2009-06-04
CN101883561B (zh) 2014-07-30
CA3031484A1 (en) 2009-06-04
HUE040596T2 (hu) 2019-03-28
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
EA019402B1 (ru) 2014-03-31
EA032767B1 (ru) 2019-07-31
HRP20130345T1 (hr) 2013-07-31
CY1113980T1 (el) 2016-07-27
EA201000914A1 (ru) 2010-12-30
CA2705408C (en) 2019-04-23
CA3031484C (en) 2021-05-04
US20180338969A1 (en) 2018-11-29
US10441558B2 (en) 2019-10-15
CA3031490A1 (en) 2009-06-04
EP3459535A1 (en) 2019-03-27
HRP20182147T8 (hr) 2019-04-19
CN104257657A (zh) 2015-01-07
US20200155491A1 (en) 2020-05-21
US8992891B2 (en) 2015-03-31
EP3459535B1 (en) 2020-08-12
CY1121183T1 (el) 2020-05-29
US10322101B2 (en) 2019-06-18
JP5953000B2 (ja) 2016-07-13
EA035711B1 (ru) 2020-07-29
TR201819564T4 (tr) 2019-01-21
ES2703508T3 (es) 2019-03-11
EP2609916A1 (en) 2013-07-03
WO2009068668A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
LT2894165T (lt) Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2240130T3 (da) Indretning til behandling af fedme
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
PL2474557T3 (pl) Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
DK2794604T3 (da) Hidtil ukendte dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af inflammatoriske lidelse
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
PL2437742T3 (pl) Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń
DK2111555T3 (da) Diagnosticering af præeklampsi
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
EP2359726A4 (en) Shower device
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
BRPI0816789A2 (pt) Goji e inflamação
EP2191756A4 (en) SHOWER DEVICE